

Blood 2024



PROGRAM BOOK

2024 Annual Scientific Meeting

27 - 30 October

Brisbane Convention and Exhibition Centre



www.blood2024.com

The combined Annual Scientific Meeting of the:



HSANZ
Haematology Society of
Australia and New Zealand



Australian & New Zealand
Society of Blood Transfusion Ltd



THANZ
Thrombosis & Haemostasis society
of Australia and New Zealand

Sponsors

Platinum Sponsors



Johnson & Johnson

Gold Sponsors

abbvie

AMGEN

AstraZeneca 

 **BeiGene**

 **NOVARTIS**

Silver Sponsors



Meeting App Sponsor



Welcome Reception Sponsor



Welcome to BLOOD 2024

We are delighted to welcome you to Brisbane for Blood 2024, the combined Annual Scientific Meeting of the Haematology Society of Australia and New Zealand (HSANZ), the Australian and New Zealand Society of Blood Transfusion (ANZSBT), and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ), together with important contributions from the HSANZ Nurses Group and the Bone Marrow Transplant Society of Australia and New Zealand.

We hope you will find the Blood 2024 program educational and stimulating, and we are very grateful to all our speakers for the willingness to share their knowledge and expertise. We would like to pay particular thanks to our international speakers who have travelled a long way to share their experience and unique insights.

We wish to thank our sponsors and exhibitors for their generous support of the Blood 2024 Meeting. Please take the time to visit the exhibition stands and interact throughout the breaks.

In true Blood fashion, the social functions will be an important part of the meeting too. Your opportunity to reconnect with old friends and meet new ones at the Welcome Function. Most exciting, get ready for an enchanting evening at our Jazz Under the Jacarandas dinner! Enjoy a night of smooth jazz, fine dining, and great company beneath the beautiful blooms of jacaranda trees.

We hope that you enjoy the many educational, social and networking opportunities that occur throughout the Meeting and leave with new knowledge and connections.

On behalf of the Local Organising Committee

Local Organising Committee

HSANZ: Andrea Henden (Convenor)

ANZSBT: Catherine Hyland & John-Paul Tung (Co-Convenors)

THANZ: Jane Mason & Michelle Spanevello (Co-Convenors)

Nurses: Jodie Marsh & Peta Parter (Co-Convenors)



HSANZ

Haematology Society of
Australia and New Zealand



Australian & New Zealand
Society of Blood Transfusion Ltd



THANZ

Thrombosis & Haemostasis society
of Australia and New Zealand

Contents

Meeting Venue	1
Social Program	4
Ancillary Meetings	5
Program Sunday 27 October	6
Program Monday 28 October	10
Program Tuesday 29 October	19
Program Wednesday 30 October	28
International Speakers	30
Orators	31
General Information	32

Registration Desk

The registration desk is located in the Main Foyer of the Brisbane Convention and Exhibition Centre.

Sunday 27 October	0800-1900hrs
Monday 28 October	0730-1800hrs
Tuesday 29 October	0730-1800hrs
Wednesday 30 October	0800-1300hrs


Meeting Managers

Email:	blood@theconferencecompany.com
Telephone:	1800 193 405 (Australian Freephone) +64 9 360 1240 (International)
Postal:	Level 35, International Tower One, 100 Barangaroo Avenue, Sydney, 2000, NSW Or PO Box 90040, Auckland 1142

**THE
CONFERENCE
COMPANY**

Meeting Venue

Foyer Level



**Exhibition, Posters
& Catering** (Exhibition Hall 1)

Registration Desk
(Main Foyer)

Plenary Sessions
Great Hall (entrance via doors 6 and 8, Mezzanine Level)


Speaker Preparation Room
(M10)

Concurrent Sessions
(M1, M2, M3, M4, P1, P2, P3, P4, P5)

Microscope Viewing
(M7)


Gala Dinner
(Plaza Ballroom)

Mezzanine Level



- Exhibition, Posters
& Catering** (Exhibition Hall 1)
- Plenary Sessions**
Great Hall (entrance via doors 6 and 8, Mezzanine Level)
- Speaker Preparation Room**
(M10)
- Concurrent Sessions**
(M1, M2, M3, M4, P1, P2, P3, P4, P5)
- Microscope Viewing**
(M7)
- Gala Dinner**
(Plaza Ballroom)
- Registration Desk**
(Main Foyer)

Plaza Level



**Exhibition, Posters
& Catering** (Exhibition Hall 1)

Registration Desk
(Main Foyer)

Plenary Sessions
Great Hall (entrance via doors 6 and 8, Mezzanine Level)

Speaker Preparation Room
(M10)

Concurrent Sessions
(M1, M2, M3, M4, P1, P2, P3, P4, P5)

Microscope Viewing
(M7)

Gala Dinner
(Plaza Ballroom)

Social Program

Welcome Reception

Date: Sunday 27 October, 1730hrs – 1900hrs

Venue: Brisbane Convention and Exhibition Centre, Exhibition Hall

Tickets: Attendance inclusive with full registration fees (entry by wearing your lanyard).
Guest tickets are AU\$95 incl GST per person, available from the registration desk.

Dress code: Business casual attire

Join us for the welcome reception on Sunday evening in the Exhibition Hall after the first day of Blood! Connect with fellow attendees, meet the speakers, and enjoy great conversations in a relaxed atmosphere. This is the perfect opportunity to network and set the stage for an engaging and productive event.

The Welcome Reception is sponsored by



Gala Dinner and Awards

Date: Tuesday 29 October, 1900-late

Venue: Plaza Ballroom, Brisbane Convention and Exhibition Centre

Tickets: Delegate ticket inclusive with full registration fees.
Guest tickets are AU\$200 incl GST per person, available from the registration desk.

Dress code: Evening attire with a touch of purple and/or jazz

Get ready for an enchanting evening at our "Jazz Under the Jacarandas" dinner! Enjoy a night of smooth jazz, fine dining, and great company beneath the beautiful blooms of jacaranda trees.



Ancillary Meetings

Saturday 26 October

ANZSBT Council Meeting	0900-1200	Room M4	Closed Meeting
THANZ Scientific Workshop	0900-1730	Room P3 & 4	Attendance by registration only
ANZSBT Transfusion Practitioners Day	0930 – 1630	Room P9	Attendance by registration only
HSANZ Advanced Trainee Workshop	1100-1630	Room M2	Attendance by registration only
HSANZ Council Meeting	1400-1630	Room P5	Closed Meeting

Sunday 27 October

RCPA Supervisor Accreditation Workshop	0830 - 0930	Room P1 & 2	Open to Members
THANZ Council Meeting	1200 - 1300	Room M5 & 6	Closed Meeting
ANZSBT AGM	1200 - 1300	Room M3	Open to Members
Nurses Members Meeting	1200 - 1300	Room M1 & 2	Open to Members

Monday 28 October

THANZ AGM	1200 - 1300	Room M4	Open to Members
Myeloma Special Practice Network Meeting	1200 - 1300	Room M1 & 2	Open to Members
ALLG Session	1200 - 1300	Room P5	Open to Members

Tuesday 29 October

World Thrombosis Day Walk and Breakfast	0700 – 0830	Room M4	Open
Mindfulness Session	0730 – 0815	Room P3 & 4	Open
Blood Cancer Task Force	0730 – 0815	Room P5	Open
HSANZ AGM	1200 - 1300	Room P5	Open to Members
Apheresis Special Practice Network Meeting	1200 - 1300	Room M1 & 2	Open to Members

Wednesday 30 October

THANZ Edu Com Meeting	1300-1500	Room M1	Closed Meeting
-----------------------	-----------	---------	----------------

Meeting Program

Sunday 27 October

At a Glance

0930-1015	Morning Tea Exhibition Hall				
1015-1200	Welcome to Country, Opening and Combined Plenary: Cell and gene therapies; The promise of cure Great Hall 1 and 2				
1200-1300	Lunch Exhibition Hall				
1200-1300	ANZSBT AGM M3				
1200-1300	Nurses Members Meeting M1 and 2				
1300-1355	Barry Firkin Oration: Morbus maculosus haemorrhagicus – where are we now? Great Hall 1 and 2 <i>Robert Bird</i>				
1400-1530	HSANZ Symposium: Genomic drivers of disease (Kindly sponsored by AbbVie) Great Hall 1 and 2	ANZSBT Symposium: A global perspective of transfusion M3	THANZ Symposium: Platelets behaving badly M4	Nurses: Free communications 1 M1 and 2	BMTSAA Symposium P1 and 2
1530-1600	Afternoon Tea Exhibition Hall				
1600-1730	HSANZ Symposium: Malignancy and infection Great Hall 1 and 2	ANZSBT / HSANZ Combined Symposium: Sickle cell disease M3	THANZ Symposium: The scary haemostasis and thrombosis acronyms (TTP, CAPS, DIC) M4	Nurses Symposium: Regional and remote haematology M1 and 2	BMTSAA Free Communications P1 and 2
1730-1900	Welcome Reception Exhibition Hall (Supported by BeiGene)				

Sunday 27 October

0930 - 1015	Morning Tea	Exhibition Hall
1015 - 1200	Welcome to Country, Opening and Combined Plenary: Cell and gene therapies; The promise of cure <i>Chairs: Andrea Henden, Anastazia Keegan, Jane Mason</i>	Great Hall 1 and 2
1015	Welcome to Country	
1030	Cell and immunotherapies; paradigm shifting and curative potential	Caron Jacobson (supported by Gilead Sciences)
1050	Haemophilia gene therapy and gene editing	Guy Young
1110	Gene therapy for haemoglobinopathies, are we ready?	Anthea Greenway
1130	Survivorship	Michelle Kenyon
1200 - 1300	Lunch	Exhibition Hall
1200 - 1300	ANZSBT AGM <i>Chair: Anastazia Keegan</i>	M3
1200 - 1300	Nurses Members Meeting	M1 and 2
1300 - 1355	Barry Firkin Oration <i>Chairs: James McFadyen and Courtney Tate</i>	Great Hall 1 and 2
1300	Introduction	
1310	Barry Firkin Oration: Morbus maculosus haemorrhagicus – where are we now?	Robert Bird
1400 - 1530	HSANZ Symposium: Genomic drivers of disease (Kindly sponsored by AbbVie) <i>Chairs: Caroline McNamara and Paula Marlton</i>	Great Hall 1 and 2
1400	Genomics of myeloproliferative neoplasms	Ann Mullally
1430	Post-MPN acute myeloid leukaemia: How can we do better?	Steven Lane
1500	Genomics for risk stratification and targeted treatment in childhood leukaemia	Andy Moore
1400 - 1530	ANZSBT Symposium: A global perspective of transfusion <i>Chairs: Catherine Hyland and John-Paul Tung</i>	M3
1400	Global health and access to safe blood in lower and middle income countries	Meghan Delaney
1430	Insights into the diversity of blood donation practice across Asia	Lin Fung
1500	International provision of rare blood	Nicole Thornton

...continued overleaf

1400 - 1530	THANZ Symposium: Platelets behaving badly <i>Chairs: Marc Ellis and Freda Passam</i>	M4
1400	Targeting glycoprotein VI in arterial thrombosis and tumor metastasis	Pierre Mangin
1430	The Janus face of platelets in sepsis and inflammation	James McFadyen
1500	Ischemic endothelial necroptosis induces red blood cell hemolysis and COVID-19 microangiopathy	Yuping Yuan

1400 - 1530	Nurses: Free communications 1 <i>Chair: Jodie Marsh</i>	M1 and 2
1400	Home-based monitoring of patients following consolidation chemotherapy for acute leukaemia using wearable technology	Vanessa Donati, NO003
1418	Kikuchi-Fujimoto disease in a young African patient with sickle cell disease	Claire Dowsing, NO004
1436	Risk of secondary malignancy is real after allogeneic stem cell transplant	Teresa Garcia, NO005
1454	Developing and implementing evidence-based vascular access device guidelines	Nicole Gavin, NO006
1512	SClg patient story prompts co-design of consumer travel checklist	Melissa Riquelme, NO009

1400 - 1530	BMTSAA Symposium <i>Chairs: Natasha McVeigh and Debra Taylor</i>	P1 and 2
1400	Young matched unrelated donors improve disease free survival compared to other donor sources: A CIBMTR analysis	Karthik Nath
1420	Point of care manufacture of CAR-T products: Achievements and challenges	Cheryl Hutchins
1440	Harnessing the opportunity for concurrent completion of multiple quality activities in a cellular therapy laboratory with limited resources	Phillip Johnson
1500	An optimised approach to achieving and maintaining compliance with multiple codes	Robyn Rodwell

1530 - 1600	Afternoon Tea	Exhibition Hall
--------------------	----------------------	------------------------

1600-1730	HSANZ Symposium: Malignancy and infection <i>Chairs: Gaurav Sutrave and Joshua Tobin</i>	Great Hall 1 and 2
1600	Virus specific T cells as a platform for CAR-T	Helen Heslop
1630	Fungus-specific T cells	Gaurav Sutrave
1700	Therapeutic vulnerabilities of EBV-associated lymphomas	Maher Gandhi

...continued overleaf

1600-1730	ANZSBT / HSANZ Combined Symposium: Sick cell disease <i>Chairs: Tina Noutsos and Stephanie Anderson</i>	M3
1600	Paediatric sickle cell disease - challenges and unmet needs	Pasquale Barbaro
1630	Sickle cell disease care for adults	Mimi Yue
1700	Overcoming transfusion challenges for patients with sickle cell disease	Ina Messig
1600-1730	THANZ Symposium: The scary haemostasis and thrombosis acronyms (TTP, CAPS, DIC) <i>Chairs: John Casey and Phillip Choi</i>	M4
1600	APS / CAPS	Saskia Middeldorp
1630	TTP	Danny Hsu
1700	DIC	Ashwini Bennett
1600-1730	Nurses Symposium: Regional and remote haematology <i>Chairs: Nicole Gavin</i>	M1 and 2
1600	Self-administration of subcutaneous Bortezomib in the home setting in regional NSW: A feasibility study	Jacqueline Jagger
1618	Where the bloody hell are you - remote haematology	Kylie Grevell
1636	<i>Final presentation in this session not confirmed at time of printing</i>	
1600-1730	BMTSAA Free Communications <i>Chair: Ayse Mouminoglu</i>	P1 and 2
1600	Meditation and medication - how we circumvent HPC (A) product clumping in a processing laboratory	Rose Wong, BO002
1620	Correlation of post-thaw vCD34 and vCD3 reporting between the Westmead Blood Transplant and Cell Therapies Laboratory and other Australian Blood and Marrow Transplant Laboratories	Yi Vee Chew, BO001
1640	Long-distance transport of HPC followed by cryopreservation does not adversely impact post-thaw viable CD34 recoveries and patient outcomes	Brandon Young, BO004
1700	Stopping the stem cell collection marathon - optimising Plerixafor use in GRIFFIN-treated patients, a single centre experience	Rose Wong, BO003
1730 - 1900	Welcome Reception (Supported by BeiGene)	Exhibition Hall

Monday 28 October

At a Glance

0715-0815 Pre-registration required	Amgen Nurse Education Symposium: Acute lymphoblastic leukaemia patient therapies and journey M1 and 2			
0830-1000	<div>HSANZ Free Communications 1: Acute leukemia and MDS Great Hall 1 and 2 <i>(Kindly sponsored by Astellas Pharma)</i></div> <div>HSANZ Free Communications 2: Myeloma P1 and 2</div> <div>HSANZ Free Communications 3: CLL / Basic science lymphoid malignancy P3 and 4</div> <div>HSANZ Free Communications 4: DS/MPN/ CML/Bone marrow failure P5</div>	ANZSBT Presidential Symposium M3	THANZ Free Communications 1: Thrombosis M4 <i>(Kindly sponsored by Sobi)</i>	Nurses Symposium: Patient-centered care M1 and 2
1000-1030	Morning Tea Exhibition Hall			
1030-1200	HSANZ Presidential Symposium Great Hall 1 and 2	ANZSBT Symposium: Platelets M3	THANZ Presidential Symposium: From bench to bedside - developing novel targets/therapies M4	Nurse Symposium: Cellular therapies M1 and 2
1200-1300	Lunch Exhibition Hall			
1200-1300	THANZ AGM M4			
1200-1300	Myeloma Special Practice Network Meeting M1 and 2			
1300-1355	Ruth Sanger Oration: History redux: Humanity, harm and healing Great Hall 1 and 2 <i>Alison Street</i>			
1400-1530	<div>HSANZ Symposium: Equity and equality in care and outcomes P1 and 2 <i>(Kindly sponsored by BeiGene)</i></div> <div>HSANZ Free Communications 5: Stem cell transplantation P3 and 4</div>	ANZSBT Symposium: Adverse transfusion events M3	HSANZ / THANZ Combined Symposium: HOW collaborative: Baby on board - haematologic dilemmas in pregnancy Great Hall 1 and 2	Nurses Symposium: Novel therapies M1 and 2
1530-1600	Afternoon Tea Exhibition Hall			
1600-1730	HSANZ/ANZTCT Combined Symposium: Next generation bone marrow transplantation Great Hall 1 and 2 <i>(Kindly sponsored by Amgen)</i>	ANZSBT / THANZ Combined Symposium: Emergency transfusion and critical bleeding M3		Nurses Symposium: Pathway to NP M1 and 2
1730-1830	Poster Viewing Exhibition Hall			
1800-1900 (ticket required to attend - places limited)	HSANZ Masterclass 1: Extending access to CAR-T			P1
	HSANZ Masterclass 2: Clinical conundrums in MPN			P2
	ANZSBT Masterclass 1: Implementing patient blood management			P3 and 4
	ANZSBT Masterclass 2: Solving complex immunohaematology cases			P5
	THANZ Masterclass 1: How I treat venous thromboembolism in pregnancy and the post-partum period			M4
1930-2105 Pre-registration required	BeiGene Dinner Symposium: Managing patients on BTK inhibitors Offsite: Rydges South Bank			

Monday 28 October

0715-0815	Amgen Nurse Education Symposium: Acute lymphoblastic leukaemia patient therapies and journey Pre-registration required	M1 and 2
0830 - 1000	HSANZ Free Communications 1: Acute leukaemia and MDS (Kindly sponsored by Astellas Pharma) Chairs: Shaun Fleming and Courtney Tate	Great Hall 1 and 2
0830	Dynamic assessment of RBC-transfusion dependency (RBC-TD) improves the Molecular International Prognostic Scoring System (IPSS-M) risk stratification of MDS	Thomas Wiseman, HO066
0845	Optical genome mapping for acute myeloid leukaemia diagnostics	Vahid Pazhakh, HO043
0900	High burden of healthcare utilisation in older AML treated with first-line Venetoclax-based therapies: A real-world analysis based on the SA-MN registry	Shreyas Khanna, HO022
0915	Genomic screening in advanced haematological cancers: Lessons from the first 155 cases in the Australian Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) program	Xuan Tan, HO063
0930	Defining the spectrum of UBA1 variants in haematological malignancy	Simon Wu, HO067
0945	Clonal haematopoiesis of indeterminate potential (CHIP) is not associated with decline in kidney function in healthy older adults	Jasmine Singh, HO059
0830 - 1000	HSANZ Free Communications 2: Myeloma Chairs: Georgia McCaughan and Nicholas Weber	P1 and 2
0830	Functional High-Risk Multiple Myeloma (FHR-MM) following Lenalidomide-Bortezomib-dexamethasone (RVd) induction or bortezomib-cyclophosphamide-dexamethasone (VCD): An analysis from the Australian & New Zealand Myeloma and Related Diseases Registry (ANZ-MRDR)	Sueh-li Lim, HO028
0845	Long-term survival after Elranatamab Monotherapy in patients with relapsed or refractory Multiple Myeloma (RRMM): MagnetisMM-3	Henry Prince, HO045
0900	Real-world, multi-centre review of outcomes utilising harmonised lenalidomide, bortezomib and dexamethasone (RVd) protocols in transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM)	Samantha Kurniawan, HO024
0915	Sonrotoclax plus Dexamethasone was tolerable and demonstrated Antimyeloma activity in patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM) harboring t(11;14)	Hang Quach, HO046

...continued overleaf

0930	Ciltacabtagene autoleucel (cilta-cel) vs Standard of care (SoC) in patients with functional high-risk (FHR) Multiple Myeloma (MM): CARTITUDE-4 subgroup analysis	Hasib Siddiqi, HO058
0945	Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis	Betty Gratton, HO012

0830 - 1000	HSANZ Free Communications 3: CLL / Basic science lymphoid malignancy <i>Chairs: Masa Lasica and Emma Taylor</i>	P3 and 4
0830	Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study	Constantine S. Tam, HO061
0845	Anti-tumoural T-cell immunity against B-cell receptor neoantigens explains the superior survival of IGHV-mutated chronic lymphocytic leukaemia	Muhammed B Sabdia, HO053
0900	Continuous Venetoclax for relapsed CLL-characteristics and outcomes of long-term responders	Sean McKeague, HO033
0915	Antibiotic-induced ablation of gut microbiota in murine models of acute lymphoblastic leukaemia results in variable patterns of leukaemic cell engraftment	Cate Cheney, HO007
0930	Acquired copy number variants are highly correlated with Ph+ALL subgroups identified by transcriptomic analysis	Jacqueline Rehn, HO049
0945	The ubiquitin E3 ligase MARCH5 is a master regulator of apoptosis and its depletion potently sensitises multiple haematologic malignancies to venetoclax	Thomas Lew, HO027

0830 - 1000	HSANZ Free Communications 4: DS/MPN/CML/Bone marrow failure <i>Chairs: Victoria Ling and Ashleigh Scott</i>	P5
0830	CBL mutations in proliferative chronic myelomonocytic leukaemia cluster in the RING domain and express CD116 in CD34+ progenitor cells	Kelly Lim, HO029
0845	Engineering a human model of TET2-mutated pre-leukemic monocyte to understand the biology of chronic myelomonocytic leukemia	Maha Kamel, HO017
0900	Sensitive genomic characterisation of the clonal haematopoietic landscape in individuals with germline GATA2 haploinsufficiency	Emma R Murphy, HO036

...continued overleaf

0915	A dual targeting approach with neoepitope-directed monoclonal antibodies can improve outcomes for CALR-mutant myelofibrosis	Chloe Thompson-Peach, HO065
0930	Procoagulant platelet responses are increased in essential thrombocythaemia and decrease with cytoreduction	Ke Xu, HO069
0945	Megakaryocyte emperipolesis in MPN: Neutrophils friend or foe?	Ryan Collinson, HO008

0830 - 1000	ANZSBT Presidential Symposium <i>Chairs: Philip Crispin and Anastazia Keegan</i>	M3
0830	Towards safer neonatal transfusion with cord blood-derived cultured red blood cells	Sara Chiaretti, AO005
0845	Resuscitation of adult shocked trauma patients using major haemorrhage protocols guided by viscoelastic haemostatic assays versus standard laboratory tests	Biswadev Mitra, AO010
0900	Engineering cell culture platforms for manufacturing and testing blood cell therapies	Mark Allenby, AO001
0915	Rethinking D-positivity: Molecular testing guidelines and clinical implications	Stacie O'Brien, AO015
0930	Practice change to improve the use of irradiated red blood cells to minimise the risk of transfusion-associated graft-versus-host disease (TA-GVHD)	Sen-Pao Chang, AO004
0945	Developing a model to predict need for red blood cell (RBC) transfusion, using machine learning tools	Christopher Berry, AO003

0830 - 1000	THANZ Free Communications 1: Thrombosis <i>(Kindly sponsored by Sobi)</i> <i>Chairs: Natalie Pecheniuk and Dominic Pepperell</i>	M4
0830	Updating the algorithm: Evolution of Lupus Anticoagulant diagnosis in the days of the DOAC.	Timothy Stanton, TO018
0845	Implementation of a novel Anticoagulation Stewardship program in an Australian Intensive Care Unit.	Julianne Chong, TO009
0900	Retrospective review of thromboprophylaxis in patients undergoing urological surgery	Hadley Bortz, TO004
0915	Metabolomic Signatures as Predictors of Bleeding in Anticoagulant Therapy	Hannah Stevens, TO020
0930	Association between tissue factor pathway inhibitor (TFPI) and atherothrombotic events in patients with cardiovascular risk factors	Rowena Brook, TO006
0945	Multimodal cardiovascular risk prediction model in diabetes – incorporation of global coagulation assays outperforms HbA1c and Framingham Risk Score	Rowena Brook, TO005

...continued overleaf

0830 - 1000	Nurses Symposium: Patient-centered care <i>Chair: Natasha Clarke</i>	M1 and 2
0830	Establishing a cancer survivorship surveillance clinic: Enhancing care beyond treatment	Louise Scoleri
0900	Myeloma Australia and Myeloma Research Laboratory: Insights from laboratory tours by the myeloma community	Jo Gardiner
0930	Delayed admission model for outpatient autograft	Jodie Marsh

1000 - 1030	Morning Tea	Exhibition Hall
--------------------	--------------------	------------------------

1030-1200	HSANZ Presidential Symposium <i>Chairs: Andrea Henden, Hui-Peng Lee and Annette Neylon</i>	Great Hall 1 and 2
1030	A window study of acalabrutinib & rituximab, followed by chemotherapy & autograft (ASCT) for treatment naïve mantle cell lymphoma (MCL) patients: Results from the investigator-initiated ALLG NHL33 'Wamm' trial	Allison Barraclough, HO003
1045	MRI and neurocognitive assessment of chemobrain in acute myeloid leukaemia	Ashleigh Scott, HO055
1100	Final survival analysis of Daratumumab (DARA) plus Lenalidomide and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM): MAiA study	Hang Quach, HO047
1115	Immunotherapy plus escalating radiotherapy dose and field in relapsed lymphoma. The phase I RaDD study	Eliza Hawkes, HO014
1130	Efficacy of asciminib against ABL-rearrangement of Ph-like acute lymphoblastic leukaemia is dependent on the presence of the SH3 domain	Elias Lagonik, HO026
1145	WT1 in AML: Unraveling genetic and epigenetic contributions to disease progression and treatment	Harsh Goel, HO010

1030-1200	ANZSBT Symposium: Platelets <i>Chairs: Catherine Hyland and John-Paul Tung</i>	M3
1030	Immune functions of platelets	Rick Kapur
1100	Emerging platelet therapies	Denese Marks
1130	CLIP-II	Michael Reade

...continued overleaf

1030-1200	THANZ Presidential Symposium: From bench to bedside - developing novel targets/therapies <i>Chairs: Danny Hsu and James McFadyen</i>	M4
1030	Platelet TREM-Like Transcript-1 (TLT-1) is elevated in patients with thrombocytopenia and levels are regulated by A disintegrin and metalloprotease 17 (ADAM17) on activated platelets	Sidra Ali, TO002
1045	Heparin-induced thrombocytopenia (HIT) immune complexes induce endothelial thromboinflammation	Jose Perdomo, TO015
1100	RNA sequencing identifies differential transcriptomic signatures in platelet subpopulations and the proximal role of large GTPase dynamin in procoagulant platelet formation	Ibrahim Tohidi-Esfahani, TO022
1115	Platelet additive solutions containing phosphates alter clot stability and structure	Gael Morrow
1130	Novel adjunctive antithrombotic therapy for acute ischemic stroke	Simone Shoenwaelder
1145	Platelet $\beta 1$ and $\beta 3$ integrins are essential for hemostasis, arterial thrombosis and tumor metastasis	Pierre Mangin
1030-1200	Nurse Symposium: Cellular therapies <i>Chairs: Jodie Marsh and Gemma White</i>	M1 and 2
1030	HCT late effects prevention and screening	Michelle Kenyon
1100	Unlocking the mind's defence: Exploring the brain behind the CAR-T service	Ty Simpson
1130	Nursing-led model of care for cytopenias post CAR T-cell therapy in R/R large b-cell lymphoma: A single centre experience	Sam Van Der Linde
1200-1300	Lunch	Exhibition Hall
1200-1300	THANZ AGM	M4
1200-1300	Myeloma Special Practice Network Meeting	M1 and 2
1300-1355	Ruth Sanger Oration <i>Chair: Anastazia Keegan</i>	Great Hall 1 and 2
1300	Introduction	Anastazia Keegan and Philip Crispin
1310	Ruth Sanger Oration: History redux: Humanity, harm and healing	Alison Street

...continued overleaf

1400-1530	HSANZ Symposium: Equity Diversity and Inclusion (Kindly sponsored by BeiGene) <i>Chairs: Nada Hamad and Mimi Yue</i>	P1 and 2
1400	Teletrials	Kaye Hewson
1430	The disparity of rural/remote Australians with haematological malignancies	Leah Peters
1500	Novel trials platforms	Charles Craddock

1400-1530	HSANZ Free Communications 5: Stem cell transplantation <i>Chairs: Stewart Hunt and Jane Royle</i>	P3 and 4
1400	Nivallo: A prospective phase I study of Nivolumab to promote the graft versus tumour effect in Haematological Malignancies persisting or progressing after Allogeneic stem cell transplantation.	David Ritchie, HO051
1415	A Prospective Assessment of Quality of Life in People with Multiple Sclerosis following Autologous Haematopoietic Stem Cell Transplant	Nabin Karki, HO018
1430	Serum Biomarkers ST2, REG3a, and MAGIC Algorithm Probability (MAP) Kinetics Predict Non-Relapse Mortality (NRM) in Allogeneic Stem Cell Transplant Patients Independent of Acute Graft-Versus-Host-Disease (aGVHD).	Joanne Tan, HO062
1445	A randomised trial of Topical Polaprezinc to prevent Oral Mucositis in patients undergoing Haematopoietic Stem Cell transplantation	Midori Nakagaki, HO037
1500	Transplant in Paediatric Haemaglobinopathy: The RCH experience	Elizabeth Prime, HO044
1515	PBSC mobilisation and ASCT outcomes following VRD and Cyclo+G or G-CSF alone in myeloma (MM)	Wei Xia, HO068

1400-1530	ANZSBT Symposium: Adverse transfusion events <i>Chairs: Simon Benson and Amanda Ormerod</i>	M3
1400	Adverse transfusion reactions	Meghan Delaney
1430	Laboratory investigation of severe adverse transfusion reactions	Kylie Fitch
1500	TRALI and TACO	Rick Kapur

1400-1530	HSANZ / THANZ Combined Symposium: HOW collaborative: Baby on board - haematologic dilemmas in pregnancy <i>Chairs: Renee Eslick and Michelle Spanevello</i>	Great Hall 1 and 2
1400	Thrombosis in pregnancy	Saskia Middeldorp
1430	Haematologic malignancies in pregnancy	Giselle Kidson-Gerber
1500	Bleeding disorders and pregnancy	Jennifer Curnow

...continued overleaf

1400 - 1530	Nurses Symposium: Novel therapies <i>Chairs: Kylie Grevell</i>	M1 and 2
1400	Navigating the challenges in delivering bi-specific antibodies at an outer metropolitan hospital	Megan Harris
1430	Developing evidence-based guidelines	Molly Robertson
1500	Nurse-led change: The development of an outpatient venetoclax ramp up pathway	Emily Minopoulos
1530-1600	Afternoon tea	Exhibition Hall
1600-1730	HSANZ/ANZTCT Combined Symposium: Next generation bone marrow transplantation <i>(Kindly sponsored by Amgen)</i> <i>Chairs: Nada Hamad and Siok Tey</i>	Great Hall 1 and 2
1600	Strategies to improve transplant outcomes in AML	Charles Craddock
1630	Next generation GVHD prevention	Robert Zeiser
1700	Translational BMT program and discovery in Australia	David Ritchie
1600-1730	ANZSBT / THANZ Combined Symposium: Emergency transfusion and critical bleeding <i>Chairs: Anastazia Keegan and Joanne Perel</i>	M3
1600	Fibrinogen conc vs. cryoprecipitate	Gael Morrow
1630	Pre-hospital transfusion	Fran Williamson
1700	What's the evidence for factor concentrates in critical bleeding?	James Winearls
1600-1730	Nurses Symposium: Pathway to NP <i>Chair: Jodie Marsh</i>	M1 and 2
1600	Case presentations from candidate to experienced NP	Panellists: Nicole Loft, Victoria Millikan, Kari Mudie, Gemma White
1700	Open questions	
1730-1830	Poster Viewing	Exhibition Hall
1800-1900	HSANZ Masterclass 1	P1
1800	Extending access to CAR-T	Helen Heslop
1800-1900	HSANZ Masterclass 2	P2
1800	Clinical conundrums in MPN	Ann Mullally

...continued overleaf

1800-1900	ANZSBT Masterclass 1	P3 and 4
1800	Implementing patient blood management	Denise Mckeown
1800-1900	ANZSBT Masterclass 2	P5
1800	Solving complex immunohaematology cases	Nicole Thornton
1800-1900	THANZ Masterclass 1 <i>Chair: Caroline Wilson</i>	M4
1800	How I treat venous thromboembolism in pregnancy and the post-partum period	Saskia Middeldorp

Please note: Masterclasses are not included in the full registration and are an additional cost. Please see the Registration Desk if you would like to attend.

1930-2105	BeiGene Dinner Symposium: Managing patients on BTK inhibitors Pre-registration required	Rydges South Bank
------------------	---	--------------------------

Brisbane city skyline



Tuesday 29 October

At a Glance

0700-0830	World Thrombosis Day Walk and Breakfast M4			
0730-0815	Mindfulness Session P3 and 4			
0830-1000	<p>HSANZ Symposium: Novel therapeutic approaches for myeloid malignancy Great Hall 1 and 2 (Kindly sponsored by Novartis)</p> <p>HSANZ Free Communications 6: Aggressive lymphoma P1 and 2 (Kindly sponsored by Roche)</p> <p>HSANZ Free Communications 7: Supportive care - functional assessment and treatment optimisation P5</p>	<p>ANZSBT Free Communications 1: Clinical transfusion M3</p> <p>ANZSBT Free Communications 2: Laboratory / scientific P3 and 4</p>	<p>THANZ Free Communications 2: Platelet and endothelial cells M4</p>	<p>Nurses Symposium: Apheresis M1 and 2</p>
1000-1030	Morning Tea Exhibition Hall			
1030-1200	<p>HSANZ Free Communications 8: Albert Baikie Memorial Medal Great Hall 1 and 2</p> <p>HSANZ Free Communications 9: Low-grade lymphoma P1 and 2</p> <p>HSANZ Free Communications 10: Supportive care - infectious disease and treatment toxicity P3 and 4</p>	<p>ANZSBT Symposium: Immunoglobulin M3</p>	<p>THANZ Symposium: Advances in vascular medicine - MDT approach M4</p>	<p>Nurses Free Communications 2 M1 and 2</p>
1200-1300	Lunch Exhibition Hall			
1200-1300	HSANZ AGM P5			
1200-1300	Apheresis Special Practice Network Meeting M1 and 2			
1300-1355	Carl de Gruchy Oration: A series of fortunate events Great Hall 1 and 2 Paula Mariton			
1400-1530	<p>HSANZ Symposium: CLL and haematology in older persons Great Hall 1 and 2 (Kindly sponsored by AstraZeneca)</p> <p>HSANZ Free Communications 11: Pre-clinical cell biology and novel diagnostic approaches P3 and 4</p>	<p>QA-Laboratory Haematology P1 and 2</p>	<p>ANZSBT Symposium: Getting blood out the door M3</p>	<p>THANZ Free Communications 3: Bleeding M4 (Kindly sponsored by Novo Nordisk)</p> <p>Nurses Symposium: Nurse support and education M1 and 2</p>
1530-1600	Afternoon Tea Exhibition Hall			
1600-1700	<p>HSANZ Symposium: Myeloma Great Hall 1 and 2</p>	<p>ANZSBT Symposium: It's a bloody disaster! M3</p>	<p>THANZ Symposium: Anticoagulation challenges M4</p>	<p>Nurses Symposium: PostMan MDT case studies and panel M1 and 2</p>
1730-1830 (ticket required to attend - places limited)	HSANZ Masterclass 3: CAR T-cells in lymphoma: Real world cases			P1
	HSANZ Masterclass 4: Finally time for T cell therapy in CLL?			P2
	HSANZ Masterclass 5: Transplant in AML: Who, when and how			P3 and 4
	HSANZ Masterclass 6: The treatment of monoclonal gammopathies in Spain under a universal healthcare system			P5
	THANZ Masterclass 2: How I treat paediatric venous thromboembolism			M4
1900-2345	Gala Dinner and Awards Plaza Ballroom			

Tuesday 29 October

0700 - 0830	World Thrombosis Day Walk and Breakfast	M4
0730 - 0815	Mindfulness Session	P3 and 4
0830 - 1000	HSANZ Symposium: Novel therapeutic approaches for myeloid malignancy (Kindly sponsored by Novartis) <i>Chairs: Piers Blombury and Joel Wight</i>	Great Hall 1 and 2
0830	Novel therapeutic approaches in MPN	Ann Mullally
0900	MRD in AML	Sun Loo
0930	What to target in myelodysplasia - shotgun or bulls eye?	Anoop Enjeti
0830 - 1000	HSANZ Free Communications 6: Aggressive lymphoma (Kindly sponsored by Roche) <i>Chairs: Stephen Boyle and Chan Cheah</i>	P1 and 2
0830	Impact of bridging therapy on outcome following chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) in third-line and beyond: An Australian single-centre real-world experience	Hamish Scott, HO056
0845	Combination treatment with novel BCL2 inhibitor sonrotoclast (BGB-11417) and zanubrutinib induces high rate of complete remission in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)	Constantine S. Tam, HO060
0900	Single-institution experience of steroid use in the management of chimeric antigen receptor (CAR) T-cell therapy toxicity for relapse/refractory (R/R) large B-cell lymphoma (LBCL)	Brydon Panozzo, HO041
0915	Pembrolizumab plus the anti-LAG-3 antibody favezelimab for patients with heavily pretreated anti-PD-1-refractory classical Hodgkin lymphoma (cHL): Updated analysis of a phase 1/2 study	Colm Keane, HO020
0930	Overcoming barriers in delivering treatment for patients with DLBCL in outer metropolitan hospitals – the Rockingham General Hospital (RGH) experience	Claire Tay, HO064
0945	Pembrolizumab plus the anti-LAG-3 antibody favezelimab in patients with anti-PD-1-naïve relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): Updated analysis of a phase 1/2 study	Gareth P. Gregory, HO013
0830 - 1000	HSANZ Free Communications 7: Supportive care - functional assessment and treatment optimisation <i>Chairs: Victoria Ling and Nirija Ranjit Anderson</i>	P5
0830	More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: The MY-PROMPT-2 trial	Elizabeth Moore, HO034
0845	Implementation of Frailty Screening and Comprehensive Geriatric Assessment (CGA) service in older people with haematological cancer in an acute care hospital- Opportunities and challenges	Gopika Krishnamurthy, HO023

...continued overleaf

0900	Virtual Chemotherapy Day Unit (VCDU): Functionality, safety and experience	Laura Jones, HO016
0915	An individualised exercise intervention improves health outcomes for people with multiple myeloma: The MyeEx randomised waitlist-controlled trial	Jennifer Nicol, HO039
0930	Frailty and comorbidity are significant prognostic factors in adult haemophagocytic lymphohistiocytosis: A multi-centre retrospective study	Tomas Mahaliyana, HO032
0945	The EpiMAP myeloma model: A new tool for predicting the impact of changes to the multiple myeloma treatment pathway	Adam Irving, HO015

0830 - 1000	ANZSBT Free Communications 1: Clinical transfusion <i>Chairs: Rebecca McLean and Amanda Ormerod</i>	M3
0830	Overcoming barriers to support patients to access subcutaneous immunoglobulin in Australia	Vesna Morosin, AO012
0845	Blood volume in preterm infants is substantially lower than estimates in current clinical guidelines	Tam Nguyen, AO013
0900	Red cell alloimmunisation and haemolytic disease of the fetus and newborn in First Nations, rural and remote mothers and babies in the Northern Territory	Tina Noutsos, AO014
0915	What's steps and healthcare resources are required to give red blood cell (RBC) transfusion? A prospective time-based activity-driven study of transfusion in patients with myelodysplastic syndromes (MDS)	Allison Mo, AO011
0930	SClg in the scrub: What matters to patients	Karen Beattie, AO002
0945	Blood transfusion practices in intensive care units: A prospective observational bi-national study	Andrew Flint, AO008

0830 - 1000	ANZSBT Free Communications 2: Laboratory / scientific <i>Chairs: Alison Badger and Philip Crispin</i>	P3 and 4
0830	High-throughput genotyping of blood donor antigens: Red cells, platelets, neutrophils and leucocytes	Candice Davison, AO006
0845	The fibrinolytic potential of cryopreserved platelets	Lacey Johnson, AO009
0900	RH blood group genetic diversity in a Kenyan donor population: Implications for chronically transfused patients in Kenya	Sandra Sowah, AO018
0915	What we learnt from setting up a Blood Bank in Australia's First Heart hospital	Vana Papasimeon, AO016
0930	The effects of storage and leucoreduction on packed red cell (PRBC) and risk of supernatant-mediated TRALI	Filip Radenkovic, AO017
0945	Environmental impacts of patient blood management: Uncovering sustainability risks with LCA analysis. Shall we be concerned?	Joyisa Deb, AO007

...continued overleaf

0830 - 1000	THANZ Free Communications 2: Platelet and endothelial cells <i>Chairs: Robert Bird and Brian Dale</i>	M4
0830	New blood-flow assays to study the intrinsic thrombogenicity of stents	Pierre Mangin
0845	Plasma proteome profiling of patients with Vaccine Induced Immune Thrombotic Thrombocytopenia (VITT) reveals alterations in complement and platelet signalling pathways	Charithani Keragala, TO011
0900	Platelet biogenesis in human health and disease	Tishya Indran, TO010
0915	Ribosome biogenesis inhibition aids in the differentiation of stem cells towards the MK/platelet lineage	Vijay Bhoopalan, TO003
0930	The role of endoplasmic reticulum stress in platelet production	Yvonne Kong, TO012
0945	Antiphospholipid Syndrome-related ischaemic stroke is associated with complement activation and platelet hyperreactivity	Ibrahim Tohidi-Esfahani, TO021

0830 - 1000	Nurses Symposium: Apheresis <i>Chair: Andrew Steele</i>	M1 and 2
0830	Sickle cell disease (SCD): A 21-year old patient's journey from Zambia to red cell exchange and everything in between	Andrew Scullion
0900	The management of adult congenital TTP with recombinant ADAMST13: An advanced nurse prospective	Patricia Wise
0930	Leukodepletions: The last 10 years at the Royal Brisbane and Women's Hospital (RBWH)	Maxine Scarffe

1000 - 1030	Morning Tea	Exhibition Hall
--------------------	--------------------	------------------------

1030-1200	HSANZ Free Communications 8: Albert Baikie Memorial Medal <i>Chairs: Hui-Peng Lee and Annette Neylon</i>	Great Hall 1 and 2
1030	Gut dysbiosis may adversely impact treatment responses with TKIs in ABL-rearranged high-risk B-ALL	Elyse Page, HO040
1045	Quantitative detection of KMT2A-rearranged measurable residual disease has strong prognostic impact prior to allogeneic haematopoietic cell transplantation (HCT) in acute myeloid leukaemia (AML)	Sun Loo, HO030
1100	High tumour-intrinsic expression of STING underpins potent and TP53 independent pro-apoptotic activity by STING agonists in primary AML	Yin Yuan, HO070
1115	Developing precision CRISPR-Cas13-based RNA therapeutics for haematological malignancies	Joshua Casan, HO005

...continued overleaf

1130	RUNX1 STOP-loss mutations define a distinct prognostic subset within RUNX1-mutated acute myeloid leukaemia	Radha Ramanan, HO048
1145	Impact of socioeconomic status on utilisation of ASCT and overall survival in multiple myeloma: A report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)	Betty Gratton, HO011

1030-1200	HSANZ Free Communications 9: Low-grade lymphoma <i>Chairs: Fiona Swain and Judith Trotman</i>	P1 and 2
1030	Atezolizumab + obinutuzumab (A+O+L64:P67) with PET-directed radiotherapy (RT) for treatment-naïve follicular lymphoma (FL): The phase II FLUORO study	Colm Keane, HO021
1045	Targeting TACI signaling enhances immune function and halts chronic lymphocytic leukemia progression	Yong Sheng, HO057
1100	Practices and outcomes during a watch and wait approach for follicular lymphoma: A study from the Australasian Lymphoma Alliance	Luani Barge, HO001
1115	Mosunetuzumab demonstrates clinically meaningful outcomes in high-risk patients with heavily pre-treated relapsed/refractory (R/R) follicular lymphoma (FL) after ≥3 years of follow-up: Subgroup analysis of a pivotal phase II study	Chan Cheah, HO006
1130	Treatment outcomes and quality of life data from WhiMSICAL - the Global Waldenström's Macroglobulinemia patient-derived data registry	Ryan Low, HO031
1145	Should large cell transformation of mycosis fungoides be recognised as a separate entity? Patterns of care and patient outcomes from Australia's only quaternary service for cutaneous lymphomas	Belinda Campbell, HO004

1030-1200	HSANZ Free Communications 10: Supportive care - infectious disease and treatment toxicity <i>Chairs: Kimberly Chung and Allison Mo</i>	P3 and 4
1030	A single center retrospective analysis of valganciclovir 900mg daily for cytomegalovirus prophylaxis in high risk allo-HSCT patients	Nermen Morgan, HO035
1045	Myocarditis complicating early acute myeloid leukaemia: A case series	Luani Barge, HO002
1100	Subacute cognitive and psychological recovery from the immune effector cell associated neurotoxicity syndrome following chimeric antigen receptor T-cell (CAR-T) therapy	Valeriya Kuznetsova, HO025
1115	Supportive care research priorities for Acute Myeloid Leukaemia (AML) – results from a modified Delphi survey	Catriona Parker, HO042
1130	Co-occurrence of obesity and diabetes adversely impacts overall survival (OS) in multiple myeloma (MM) – an analysis from the Australian and New Zealand Myeloma & Related Disease Registry (ANZ MRDR)	Sabine Ringkowski, HO050

...continued overleaf

1030-1200	ANZSBT Symposium: Immunoglobulin <i>Chairs: Philip Crispin and Tina Noutsos</i>	M3
1030	ITP: Is there still a role for IVIg?	Rick Kapur
1100	Unanswered questions in immunoglobulin therapy	Zoe McQuilten
1130	Subcutaneous immunoglobulin: When and why?	Philip Crispin
1030-1200	THANZ Symposium: Advances in vascular medicine - MDT approach <i>Chairs: Melanie Jackson and Charithani Keragala</i>	M4
1030	Vascular anomalies and the surgeon	Roy Kimble
1100	Vascular anomalies and the radiologist	Kate Mahady
1130	Targeted therapy for vascular anomalies: The emerging field of vascular medicine	Jeremy Robertson
1030-1200	Nurses Free Communications 2 <i>Chair: Nicole Loft</i>	M1 and 2
1030	Driving health equity. A safe and effective shared model of care initiative following allogeneic stem cell transplantation: An Alfred Health (AH) and Northern Health (NH) collaboration	Louise Scolieri, NO010
1048	A tissue typing dilemma	Jo Cryer, NO001
1106	Elevating nursing practice: Integrating a clinical nurse specialist within a specialist nursing model of care in the myeloma and autograft service	Cornelia Joyce Dizon, NO002
1124	Pregnancy and delivery management of women who carry the haemophilia gene in Queensland	Alex Klever, NO007
1142	Oral mucositis management in haematopoietic stem cell transplantation in Australia and New Zealand (CAN EAT SURVEY)	Emma Munro, NO008
1200-1300	Lunch	Exhibition Hall
1200-1300	HSANZ AGM	P5
1200-1300	Apheresis Special Practice Network Meeting	M1 and 2
1300-1355	Carl de Gruchy Oration <i>Chair: Hui-Peng Lee</i>	Great Hall 1 and 2
1300	Introduction	
1310	Carl de Gruchy Oration: A series of fortunate events	Paula Marlton

...continued overleaf

1400-1530	HSANZ Symposium: CLL and haematology in older persons <i>(Kindly sponsored by AstraZeneca)</i> <i>Chairs: Sasanka Handunnetti and Julian Grabeck</i>	Great Hall 1 and 2
1400	The balance between efficacy, toxicity and quality of life in the treatment landscape of CLL	Arnon Kater <i>(supported by Johnson & Johnson)</i>
1430	Myeloma and CLL	Andrew Spencer
1500	Treating acute myeloid leukaemia in older persons – through the lens of frailty	Victoria Ling

1400-1530	HSANZ Free Communications 11: Pre-clinical cell biology and novel diagnostic approaches <i>Chairs: Rakin Chowdhury and Julian Cooney</i>	P3 and 4
1400	Engineering three-dimensional scaffolds for early ex vivo erythropoiesis	Gloria Astrid Nausa Galeano, HO038
1415	Cord blood-derived microtissues as a preclinical testing platform for pediatric vascular inflammation	Rose Ann Franco, HO009
1430	Endothelial-targeted CD39 as a novel treatment for acute multi-organ injury in sepsis	Ioanna Savvidou, HO054
1445	Flow cytometric CAR-T cell enumeration and clinical correlation with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)	Matthew Rubic, HO052
1500	Clinical utility of a computerised cognitive test in identifying immune effector cell associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy	Christina Kazzi, HO019

1400-1530	QA-Laboratory Haematology <i>Chairs: John Giannoutsos and Surender Juneja</i>	P1 and 2
1400	QAP-morphology	John Giannoutsos and Loriza Khan
1430	Update on digital and machine learning in haematology morphology	Surender Juneja
1500	Integrating diagnostic reporting for haematological malignancies	Ing Soo Tiong

1400-1530	ANZSBT Symposium: Getting blood out the door <i>Chairs: Mark Dean and Helen Stathopoulos</i>	M3
1400	Supplying blood in emergencies	Samantha Lennard
1430	Why phenotypes matter in the genomics era	Nicole Thornton
1500	Antigen matching for complex transfusion patients (WAA)	Meghan Delaney

...continued overleaf

1400-1530	THANZ Free Communications 3: Bleeding <i>(Kindly sponsored by Novo Nordisk)</i> <i>Chairs: Mark Rane and Chee Wee Tan</i>	M4
1400	Single dilution one stage factor levels with reflex multi-dilution testing – feasibility, diagnostic accuracy, and cost-effectiveness of a change in coagulation testing paradigm	Timothy Stanton, TO019
1415	Adults with immune thrombocytopenia (ITP) who discontinued or switched thrombopoietin receptor agonist (TPO-RA): Outcomes from an Australian tertiary hospital	Rebecca Dring, TO007
1430	Utility of panel-based genetic sequencing in von Willebrand disease	Radha Ramanan, TO016
1445	A study to compare two methods to measure VWF:FVIII binding capacity as screening tests for von Willebrand disease type 2N	Elizabeth Duncan, TO008
1500	Successful cardiac surgery in three patients with haemophilia A on Emicizumab	Gianna Pastore, TO014
1515	Management of bleeding disorders in pregnant women: A single tertiary-centre experience	Caitlin Rice, TO017
1400-1530	Nurses Symposium: Nurse support and education <i>Chairs: Lilli Seyfried and Kylie Sih</i>	M1 and 2
1400	EBMT	Michelle Kenyon
1430	ANZTCT	Nada Hamad
1500	Burnout and wellbeing in oncology nursing	Kylie Sih
1530-1600	Afternoon Tea	Exhibition Hall
1600-1700	HSANZ Symposium: Myeloma <i>Chairs: Adam Bryant and Fiona Swain</i>	Great Hall 1 and 2
1600	CAR-T cells in multiple myeloma	Carlos Fernández de Larrea
1620	New...and old frontiers in myeloma	Amit Khot
1640	Amyloid	Peter Mollee
1600-1700	ANZSBT Symposium: It's a bloody disaster! <i>Chairs: Alison Badger and Amanda Catherwood</i>	M3
1600	Navigating major incidents	Denise Mckeown
1630	Optimising blood supply: Statewide contingency planning and strategies	Cathie Gore

...continued overleaf

1600-1700	THANZ Symposium: Anticoagulation challenges <i>Chairs: Nicola Eaddy and Sunelle Engelbrecht</i>	M4
1600	Final analysis of the prospective cohort study on patients with a haematological malignancy on anticoagulants who develop thrombocytopenia (HAT Study)	Marcus Lombard, TO013
1620	A health experience in using Andexanet Alfa to treat oral factor Xa anticoagulant-associated critical bleeding	Khalid Al-Azri, TO001
1640	Liver patients in sticky situations	Sara Ng

1600-1700	Nurses Symposium: PostMan MDT case studies and panel <i>Chairs: Michelle Kenyon and Peta Parter</i>	M1 and 2
1600	Panel discussion	Sarah Andersen Emma Foley Melissa Jensen Ross Lindell-Innes Hannah Western

1730 - 1830	HSANZ Masterclass 3	P1
1730	CAR T-cells in lymphoma: Real world cases	Caron Jacobsen <i>(supported by Gilead Sciences)</i>
1730 - 1830	HSANZ Masterclass 4	P2
1730	Finally time for T cell therapy in CLL?	Arnon Kater <i>(supported by Johnson & Johnson)</i>
1730 - 1830	HSANZ Masterclass 5	P3 and 4
1730	Transplant in AML: Who, when and how	Charles Craddock
1730 - 1830	HSANZ Masterclass 6	P5
1730	The treatment of monoclonal gammopathies in Spain under a universal healthcare system	Carlos Fernández de Larrea
1730 - 1830	THANZ Masterclass 2 <i>Chair: Jeremy Roberston</i>	M4
1730	How I treat paediatric venous thromboembolism	Guy Young

Please note: Masterclasses are not included in the full registration and are an additional cost. Please see the Registration Desk if you would like to attend.

1900-2345	Gala Dinner and Awards	Plaza Ballroom
------------------	-------------------------------	-----------------------

Wednesday 30 October

At a Glance

0900-1030	HSANZ Symposium: CAR and BITE lymphoma <i>Great Hall 1 and 2</i>	ANZSBT Symposium: Transfusion in practice <i>M3</i>	THANZ Symposium: Haemophilia in practice <i>M4</i>
1030-1100	Morning Tea <i>Exhibition Hall</i>		
1100-1245	Closing Plenary: Future state and capacity building in haematology in Australia <i>Great Hall 1 and 2</i>		



Brisbane river at twilight

Wednesday 30 October

0900 - 1030	HSANZ Symposium: CAR and BiTE lymphoma <i>Chairs: Adrian Minson and Sumi Ratnasingam</i>	Great Hall 1 and 2
0900	The great debate: CAR vs bispecifics in DLBCL and FL	Caron Jacobsen (supported by Gilead Sciences)
0930	Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results of a global randomized phase III trial (STARGLO, NCT04408638)	Gareth Gregory
1000	Beyond aggressive lymphoma	Arnon Kater (supported by Johnson & Johnson)

0900 - 1030	ANZSBT Symposium: Transfusion in practice <i>Chairs: Amanda Catherwood and Rebecca McLean</i>	M3
0900	Transfusion technology	Denise Mckeown
0930	Is it an audit or research?	Amanda Ullman
1000	PBM in ICU? Impact of small volume blood sampling	Samantha Keogh

0900 - 1030	THANZ Symposium: Haemophilia in practice <i>Chairs: Jane Mason and Dominic Pepperall</i>	M4
0900	Remember bleeds? The importance of maintaining vigilance in era of excellent prophylaxis	Guy Young
0930	Haemophilia and comorbidities	Liane Khoo
1000	Novel therapies - where do they sit in the haemophilia space	Sally Campbell

1030 - 1100	Morning Tea	Exhibition Hall
-------------	--------------------	------------------------

1100-1300	Closing Plenary: Future state and capacity building in haematology in Australia <i>Chairs: Philip Crispin, Andrea Henden and Charithani Keragala</i>	Great Hall 1 and 2
1100	Academic model for CAR-T development at hospital clinic in Barcelona: ARI0002h for multiple myeloma and beyond	Carlos Fernández de Larrea
1130	Translating inherited platelet disorders research into clinical diagnostics in NSW	Vivien Chen
1200	Engineering red cells	Rebecca Griffiths
1230	HSANZ President's closing statement	Hui-Peng Lee
1245	2024-2025 Handover	

International Speakers

HSANZ



Charles Craddock

Professor of Haemato-oncology,
University of Warwick, UK



Arnon Kater

Supported by
Johnson&Johnson

Senior Advisor, Academic
Medical Center, University of
Amsterdam, The Netherlands



Carlos Fernández de Larrea

Consultant, Hospital Clínic de
Barcelona, Spain



Ann Mullally

Associate Professor of
Medicine, Harvard Medical
School, USA



Helen Heslop

Physician-Scientist, Departments of
Medicine and Pediatrics Section of
Hematology-Oncology, CAGT, Baylor
College of Medicine, USA



Robert Zeiser

Director of The Division of
Tumor Immunology and Stem
Cell Transplantation, Medical
Center-University of Freiburg,
Germany



Caron Jacobson

Supported by  **GILEAD**

Associate Professor of Medicine,
Harvard Medical School, USA

ANZSBT



Meghan Delaney

Chief of the Division of Pathology
& Laboratory Medicine, Director of
Transfusion Medicine, Children's
National Hospital, USA



Denise Mckeown

Regional Haemovigilance Co-
ordinator/ Manager of BHSC
Haemovigilance Team, Royal
Victoria Hospital, UK



Rick Kapur

Research Group Leader, Sanquin
Research and Amsterdam UMC,
The Netherlands



Nicole Thornton

Head of Red Cell Reference,
IBGRL, NHS Blood and
Transplant, UK

THANZ



Pierre Mangin

Director, Inserm research unit,
France



Gael Morrow

Chancellor's Fellow at Robert
Gordon University, UK



Saskia Middeldorp

Professor of Medicine and Head
of the Department of Internal
Medicine, Radboud University
Medical Center, The Netherlands



Guy Young

Director, Hemostasis and
Thrombosis Center / Clinical
Coagulation Laboratory, Children's
Hospital Los Angeles, USA

Nursing



Michelle Kenyon

Consultant Nurse, Kings College
Hospital, NHS Foundation Trust, UK

Orators



Barry Firkin Orator

Robert Bird

Haematologist, Princess Alexandra Hospital, QLD



Carl De Gruchy Orator

Paula Marlton

Director of Haematology and Head of Leukaemia, Princess Alexandra Hospital, QLD



Ruth Sanger Orator

Alison Street

Monash University, VIC